More than a partner: How Labcorp Central Laboratories managed the 65-day Shanghai lockdown

With five global central laboratories, Labcorp understands the value of around-the-clock support to advance clinical trial testing, but the recent 65-day lockdown at their Shanghai facilities gave new meaning to “around the clock.”

Cell and Gene Therapy Answers: Bioanalytical support for cell and gene therapy

We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp drug development, regarding bioanalytical support for cell and gene therapy modalities. He shared some of the current challenges in cell and gene therapy, how the Labcorp Bioanalytical Services group contributes to the development of cell and gene therapy and the path forward as new treatments continue to be developed.

Labcorp to open new kit production innovation base in Suzhou, China

In late July, Labcorp joined the signing ceremony of its kit production innovation base project in Suzhou New District, China. The event was held and organized by the Suzhou New District government and saw attendance from city leadership officials, including Deputy Mayor of Suzhou city, Mr. Xiaodong Tang.

snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services

Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical.  This module represents a cross-functional effort to develop a solution digitizing the at-home trial service workflow. Namely, the module seeks to accelerate requesting and assigning country-level resources, facilitate visit completion with a native application to accelerate data availability and ultimately decrease manual processes when leveraging at-home clinical services such as nursing and biological specimen collection. By leveraging an all-in-one DCT platform combining eSource with eConsent, ePRO and telemedicine, Labcorp DCTs are able to provide solutions tailored to the needs of patient populations; investigators and sites are also able to access and review data from a single access point. This new module embodies the “built-in, not bolted-on” approach that Labcorp DCTs have pioneered.

European Society for Medical Oncology: Understanding barriers to accessible cancer care

The European Society for Medical Oncology (ESMO) recently held its first in-person congress since the COVID-19 pandemic. The conference, held in Paris, brought together more than 22,000 attendees to share and discuss the latest evidence and issues in cancer care. A common thread running through the congress program was ESMO’s Vision 2025—a commitment of “shared determination to secure the best possible outcomes for patients.” Vision 2025 outlines a three-tiered approach to achieving this:

Exploring metastatic breast cancer immunotherapies: Are ADCs and ICIs the answer?

Breast cancer is the most common malignancy in women and the second most common cancer worldwide.1 Rates of breast cancer are increasing in many parts of the world, reflecting its association with social and lifestyle factors related to economic development, as well as increases in life expectancy.2

How patient-centricity embeds value and stability in LTFU studies

Phase I-III randomized controlled trials alone are not generating enough data to extrapolate conclusions and theories about therapeutics to the global population. Not all drugs demonstrate the same efficacy in the real world as shown in the clinical trials. Because of this, we are seeing a rise in long-term follow-up (LTFU) studies that follow patient responses to a given treatment over five, 10 or 15 years, depending on the treatment.

Biomarker Q&A: The power of precision medicine for kidney disease

Labcorp Drug Development has continued to invest in the technology, capacity and expertise globally to support the evolving and complex analytical needs of our clients. We recently spoke with Katherine T Landschulz, PhD, Sr. Director and Lead Scientist, Cardiovascular and Metabolic Disease, Neurodegeneration at Labcorp Drug Development, to learn about the power of emerging biomarkers and new opportunities for precision medicine approaches in kidney disease. 

Labcorp Named One of the World's Most Admired Companies™ by FORTUNE® Magazine

BURLINGTON, N.C. , Feb. 1, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has once again been named to FORTUNE® magazine's list of the World's Most Admired Companies™, a recognition of the most respected and reputable companies

What the latest changes to EU regulations and data requirements mean for your microbial biopesticide registrations and renewals

Despite perceptions that biopesticides are inherently less dangerous, the EU regulates them as stringently as conventional, potentially highly hazardous, synthetic plant protection chemicals (Regulation [EC] No. 1107/2009). This has made approvals costly and slow. Recent regulatory revisions intended to redress this—to give EU farmers better and faster access to biological alternatives—may paradoxically increase the regulatory burden. Read on to learn what this may mean for registration or renewal of your biopesticide.